Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey C Farrell

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
The Medical Journal of Australia|March 14, 2003
Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic settingDinesh Kumar, Craig Wallington-Beddoe, Jacob George, et al.
Hepatology (Baltimore, Md.)|September 16, 2004
Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in miceRobert S McCuskey, Yoshiya Ito, Graham R Robertson, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelinesShivakumar Chitturi, Geoffrey C Farrell, Etsuko Hashimoto, et al.
Hepatology (Baltimore, Md.)|July 30, 2011
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Hossein Poustchi, Geoffrey C Farrell, Simone I Strasser, et al.
Journal of Gastroenterology and Hepatology|September 21, 2011
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitisClaire Z Larter, Matthew M Yeh, Derrick M Van Rooyen, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
How should we manage patients with non-alcoholic fatty liver disease in 2007?Henry L-Y Chan, H Janaka de Silva, Nancy W-Y Leung, et al.
Journal of Gastroenterology and Hepatology|October 16, 2008
Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infectionJun-ping Shi, Jian-gao Fan, Rui Wu, et al.
Clinical Science (London, England : 1979)|November 3, 2016
Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese miceLaurence Poekes, Vanessa Legry, Olivier Schakman, et al.
Journal of Gastroenterology and Hepatology|August 8, 2002
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infectionJason M Hui, James Kench, Geoffrey C Farrell, et al.
Journal of Gastroenterology and Hepatology|April 12, 2013
Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesisSharon Pok, Victoria Wen, Nicholas Shackel, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
The Medical Journal of Australia|March 14, 2003
Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic settingDinesh Kumar, Craig Wallington-Beddoe, Jacob George, et al.
Hepatology (Baltimore, Md.)|September 16, 2004
Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in miceRobert S McCuskey, Yoshiya Ito, Graham R Robertson, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelinesShivakumar Chitturi, Geoffrey C Farrell, Etsuko Hashimoto, et al.
Hepatology (Baltimore, Md.)|July 30, 2011
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?Hossein Poustchi, Geoffrey C Farrell, Simone I Strasser, et al.
Journal of Gastroenterology and Hepatology|September 21, 2011
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitisClaire Z Larter, Matthew M Yeh, Derrick M Van Rooyen, et al.
Journal of Gastroenterology and Hepatology|June 15, 2007
How should we manage patients with non-alcoholic fatty liver disease in 2007?Henry L-Y Chan, H Janaka de Silva, Nancy W-Y Leung, et al.
Journal of Gastroenterology and Hepatology|October 16, 2008
Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infectionJun-ping Shi, Jian-gao Fan, Rui Wu, et al.
Clinical Science (London, England : 1979)|November 3, 2016
Defective adaptive thermogenesis contributes to metabolic syndrome and liver steatosis in obese miceLaurence Poekes, Vanessa Legry, Olivier Schakman, et al.
Journal of Gastroenterology and Hepatology|August 8, 2002
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infectionJason M Hui, James Kench, Geoffrey C Farrell, et al.
Journal of Gastroenterology and Hepatology|April 12, 2013
Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesisSharon Pok, Victoria Wen, Nicholas Shackel, et al.
Pageof 13